click on circles to display study description...
abiraterone plus ADT (n=-9) vs. androgen deprivation therapy (ADT) (n=-9)
randomized controlled trial
abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily)
ADT alone
metastatic, hormone-sensitive prostate cancer
52% of the patients had metastatic disease, 20% had node-positive or node-indeterminate nonmetastatic disease, and 28% had node-negative, nonmetastatic disease; 95% had newly diagnosed disease
abiraterone plus ADT (n=-9) vs. androgen deprivation therapy (ADT) (n=-9)
randomized controlled trial
androgen-deprivation therapy plus abiraterone acetate (1000 mg daily, given once daily as four 250-mg tablets) plus prednisone (5 mg daily)
androgen-deprivation therapy plus dual placebos
metastatic, hormone-sensitive prostate cancer
abiraterone plus docetaxel plus ADT (n=355) vs. docetaxel plus ADT (n=355)
randomized controlled trial
abiraterone androgen deprivation therapy with docetaxel population
androgen deprivation therapy with docetaxel population
metastatic, hormone-sensitive prostate cancer
apalutamide plus ADT (n=525) vs. androgen deprivation therapy (ADT) (n=527)
randomized controlled trial
metastatic, hormone-sensitive prostate cancer
double-blind
darolutamide plus doxetaxel plus ADT (n=651) vs. docetaxel plus ADT (n=655)
randomized controlled trial
darolutamide, androgen-deprivation therapy, and docetaxel
androgen-deprivation therapy, and docetaxel
metastatic, hormone-sensitive prostate cancer
double-blind
docetaxel plus ADT (n=-9) vs. androgen deprivation therapy (ADT) (n=-9)
-
metastatic, hormone-sensitive prostate cancer
docetaxel plus ADT (n=397) vs. androgen deprivation therapy (ADT) (n=393)
randomized controlled trial
metastatic, hormone-sensitive prostate cancer
docetaxel plus ADT (n=-9) vs. androgen deprivation therapy (ADT) (n=-9)
-
metastatic, hormone-sensitive prostate cancer
docetaxel plus ADT (n=-9) vs. androgen deprivation therapy (ADT) (n=-9)
randomized controlled trial
docetaxel and androgen-deprivation therapy (ADT)
androgen-deprivation therapy (ADT) alone
ADT (orchiectomy or luteinising hormone-releasing hormone agonists, alone or combined with non-steroidal antiandrogens) alone
metastatic, hormone-sensitive prostate cancer
enzalutamide plus ADT (n=-9) vs. androgen deprivation therapy (ADT) (n=-9)
randomized controlled trial
enzalutamide plus testosterone suppression
standard nonsteroidal antiandrogen therapy
(bicalutamide, nilutamide, or flutamide)
metastatic, hormone-sensitive prostate cancer
enzalutamide plus ADT (n=574) vs. androgen deprivation therapy (ADT) (n=576)
randomized controlled trial
metastatic, hormone-sensitive prostate cancer
powered by vis.js Network